A Phase 3, Open-Label, Multicenter, Randomized Study of Subcutaneous vs Intravenous Tarlatamab in Participants with Relapsed Extensive-Stage Small Cell Lung Cancer After Platinum-based First-line chemotherapy (DeLLphi-315)
Phase: Phase III clinical trials
Principal Investigator: Dott. Occhipinti Mario
Main Facility: Oncologia Medica 1
Drug: Tarlatamab (AMG 757)
Pathologies: Lung cancer
ClinicalTrials.gov: Read the details about clinical trials
A Phase 3, open-label, multicenter, randomized clinical study aimed at comparing subcutaneous versus intravenous administration of tarlatamab (AMG 757) in adult patients with relapsed extensive-stage small-cell lung cancer (ES-SCLC). The study comprises two treatment arms and targets a patient population whose disease has progressed after receiving platinum-based first-line chemotherapy. The primary objective of the trial is to demonstrate the non-inferiority of the pharmacokinetic (PK) parameters of the subcutaneous formulation compared to the intravenous one, while simultaneously characterizing the efficacy, safety, and tolerability of the subcutaneous administration. Participant randomization is stratified, and the study is being conducted internationally across multiple clinical centers.
Last update: 06/10/2026